Scholar Rock Aktie

37,40 EUR -1,20 EUR -3,11 %

11.03.2026

BMN

43,00 USD -0,17 USD -0,39 %

nachbörslich00:25:23

BTT

Scholar Rock jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.3,93 Mrd. EUR

Div. Rendite0,00%

WKNA2JMQW

ISINUS80706P1030

SymbolSRRK

Scholar Rock Aktien News

Sortieren:Datum Meistgelesen

08.01.25BusinesswireScholar Rock Highlights 2025 Strategic Priorities

02.01.25BusinesswireScholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference

13.12.24BusinesswireScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WerbungScholar Rock-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.11.24BusinesswireScholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress

04.11.24BusinesswireScholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin

01.11.24BusinesswireScholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

31.10.24BusinesswireScholar Rock to Participate in Upcoming Investor Conferences

31.10.24BusinesswireScholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting

22.10.24BusinesswireScholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering

09.10.24BusinesswireScholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded Warrants

07.10.24BusinesswireScholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

07.10.24BusinesswireScholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

10.09.24BusinesswireScholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

04.09.24BusinesswireScholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

29.08.24BusinesswireScholar Rock to Participate in Upcoming Investor Conferences

08.08.24BusinesswireScholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

23.07.24BusinesswireScholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

22.05.24BusinesswireScholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

20.05.24BusinesswireScholar Rock to Participate in Upcoming Investor Conferences

14.05.24BusinesswireScholar Rock to Host Investor Day on May 22, 2024

07.05.24BusinesswireScholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

19.03.24BusinesswireScholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

28.02.24BusinesswireScholar Rock to Participate in Upcoming Investor Conferences

15.02.24BusinesswireScholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

12.01.24BusinesswireScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04.01.24BusinesswireScholar Rock Provides Corporate Update and Highlights Priorities for 2024

19.12.23BusinesswireScholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference

07.11.23BusinesswireScholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

02.11.23BusinesswireScholar Rock to Participate in Upcoming Investor Conferences

23.10.23BusinesswireScholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

16.10.23BusinesswireScholar Rock Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

12.10.23BusinesswireScholar Rock Announces Pricing of Upsized Public Offering of Common Stock

11.10.23BusinesswireScholar Rock Announces Proposed Public Offering of Common Stock

11.10.23BusinesswireScholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

09.08.23BusinesswireScholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress

30.06.23BusinesswireNew 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular Atrophy

01.06.23BusinesswireScholar Rock to Present at the Jefferies Healthcare Conference

09.05.23BusinesswireScholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress

10.04.23BusinesswireScholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

Scholar Rock News

Scholar Rock News: auf dieser Seite finden Sie alle Scholar Rock News und Nachrichten zur Scholar Rock Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Scholar Rock News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Scholar Rock News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.